Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT05829616 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors

Start date: April 17, 2023
Phase: Phase 1
Study type: Interventional

This study is a single-arm, open, dose-escalation, and dose-expansion phase I clinical trial of QLS12004 in patients with advanced solid tumors, designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of QLS12004 in subjects with advanced solid tumors.

NCT ID: NCT05828303 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

Start date: June 28, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study to evaluate the potential drug-drug interaction (DDI) effect of repotrectinib on certain drug transporters in patients with advanced cancer.

NCT ID: NCT05824975 Recruiting - Clinical trials for Advanced Solid Tumor

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 in Patients With Advanced Solid Tumors

Start date: May 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent over a range of advanced and/or metastatic solid tumors.

NCT ID: NCT05824663 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors

Start date: May 2023
Phase: Phase 1
Study type: Interventional

This is a study to evaluate the safety and tolerability of the study drug HBM1020 which contains two parts. Part 1 will enroll solid tumor participants and Part 2 will enroll renal cell carcinoma (RCC) and colorectal adenocarcinoma (CRC).

NCT ID: NCT05821777 Recruiting - Clinical trials for Advanced Solid Tumor

A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors

Start date: March 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess safety, tolerability, and preliminary activity of LB101 monotherapy in participants with advanced solid tumors.

NCT ID: NCT05819684 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors

Start date: April 18, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label, three-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-4602 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.

NCT ID: NCT05809336 Completed - Clinical trials for Advanced Solid Tumor

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Start date: May 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

We conducted a single-center, prospective randomized ,Parallel controls, open labels Clinical Studies,The study is about Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients with malignant Advanced Solid Tumors .One group was the inosine group , the other group was the non-inosine group.The treatment regimen of inosine group : inosine + PD-1/PD-L1 inhibitor ± chemotherapy/targeting, and the treatment regimen of non-inosine group : PD-1/PD-L1 inhibitor ± chemotherapy/targeting.The primary study endpoints were overall survival (OS) and progression-free survival PFS, and the secondary study endpoints were objective remission rate (ORR) and disease control rate (DCR) comparing the two groups.

NCT ID: NCT05805956 Recruiting - Clinical trials for Advanced Solid Tumor

IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

Start date: February 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is an open-label, multicenter, first-in-human dose-escalation and cohort expansion Phase I/II clinical study to evaluate the safety, tolerability and preliminary efficacy of IMM2902 in the treatment of HER2-expressing advanced solid tumors

NCT ID: NCT05801094 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study of QL1604 for Advanced Solid Tumors

Start date: July 20, 2020
Phase: Phase 1
Study type: Interventional

In this study, patients with advance solid tumors will be treated with QL1604 monotherapy.

NCT ID: NCT05798611 Recruiting - Clinical trials for Advanced Solid Tumor

Study of ART0380 in Patients With Biologically Selected Solid Tumors

ARTIST
Start date: September 6, 2023
Phase: Phase 2
Study type: Interventional

This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).